血のナトリウレチンペプチド濃度に対する肥満の影響
Thomas J Wang1, Martin G Larson, Daniel Levy
1Framingham Heart Study, Framingham, Mass 01702, USA.
Circulation
|February 11, 2004
まとめ
肥満の人は,ナトリウムバランスと血圧の重要な調節体であるナトリウレチンペプチドのレベルが低い. これらの低下したレベルは,高血圧および関連する疾患を発症するリスクを増加させる可能性があります.
科学分野:
- 心血管科学 心血管科学
- エンドクリノロジー エンドクリノロジー
- メタボリック障害 メタボリック障害
背景:
- 肥満は高血圧と関連しており,潜在的なメカニズムとして,ナトリウム保持と交感性過剰活性があります.
- ナトリウレチンペプチドは,ナトリウムホメオスタシスと神経ホルモンのバランスを調節し,肥満に関連する高血圧の役割を示唆しています.
- 肥満におけるナトリウレチンペプチド反応の障害が仮定されている.
研究 の 目的:
- 肥満と循環中のB型ナトリウレチンペプチド (BNP) とN末端プロアトリウムナトリウレチンペプチド (N-ANP) の関連性を調査する.
- 肥満がナトリウレチンペプチドの濃度低下と関連しているかどうかを判断し,高血圧リスクに潜在的に寄与する.
主な方法:
- プラズマのBNPとN-ANPのレベルを分析したフレミングハム研究 (Framingham Study) に参加した3389人の心不全患者.
- 多変数回帰分析は,臨床的およびエコーカルディオグラフィの要因に調整されています.
- 低ナトリウレチンペプチド濃度の分類は,検査検出限界値と性別特有の四分位数に基づいています.
主要な成果:
- 肥満の男性と女性は,痩せた人と比較してプラズマ平均のBNPとN-ANP濃度が著しく低いことを示した (傾向は男性ではP<0.0001,女性ではP<0.001).
- 肥満の個人は,痩せた個人に比べて,血BNPとN-ANPが低い確率が著しく高かった.
- 糖尿病はまた,低ナトリウレチンペプチドレベルと関連しており,肥満と併用すると,追加的な悪影響がある.
結論:
- 肥満は,ナトリウレチンペプチドの循環レベル低下と関連しています.
- 肥満患者の低ナトリウレチンペプチドレベルは,高血圧への感受性の増加に寄与する可能性があります.
- これらの発見は,肥満と高血圧および関連する疾患を結びつける潜在的なメカニズムを強調しています.
関連する概念動画
Hormonal Regulation of Blood Pressure
8.3K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
8.3K
Obesity
1.6K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Drug Dosing: Obese Patients
345
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
345
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
401
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
401
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
296
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
296
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
778
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
778


